Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families

Cancer Genetics and Cytogenetics

Volumn 138, Issue 2, 2002, Pages 120-127

  Balz, Vera ^a   Prisack, Hans Bernd ^a   Bier, Henning ^a   Bojar, Hans ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; GERMANY; HUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; TP53 GENE; TSG101 GENE; TUMOR SUPPRESSOR GENE;

ADULT; ALTERNATIVE SPLICING; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GERM-LINE MUTATION; GERMANY; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VARIATION (GENETICS);

EID: 0037110201     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00601-5     Document Type: Article

References (42)

1. Serova O.M., Mazoyer S., Puget N., Dubois V., Tonin P., Shugart Y.Y., Goldgar D., Narod S.A., Lynch H.T., Lenoir G.M. Mutations in BRCA1 and BRCA2 in breast cancer families. are there more breast cancer susceptibility genes? Am J Hum Genet. 60:1997;486-495.
2. Schubert E.L., Lee M.K., Mefford H.C., Argonza R.H., Morrow J.E., Hull J., Dann J.L., King M.-C. BRCA2 in American families with four or more cases of breast and ovarian cancer. recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2 Am J Hum Genet. 60:1997;1031-1040.
3. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M.D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T.R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B.A.J., Gayther S.A., Birch J.M., Lindblom A., Stoppa-Lyonnet D., Bignon Y., Borg A., Hamann U., Haites N., Scott R.J., Maugard C.M., Vasen H., Seitz S., Cannon-Albright L.A., Schofield A., Zelada-Hedman M., the Breast Cancer Linkage Consortium Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 62:1998;676-689.
4. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumor types. Nature. 342:1989;705-708.
5. Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni-Syndrome. Nature. 348:1990;747-749.
6. Sidransky D., Tokino T., Helzlsouer K., Zehnbauer B., Rausch G., Shelton B., Prestigiacomo L., Vogelstein B., Davidson N. Inherited p53 gene mutations in breast cancer. Cancer Res. 52:1992;2984-2986.
7. Li L., Li X., Francke U., Cohen S.N. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell. 88:1997;143-154.
8. Lee M.P., Feinberg A.P. Aberrant splicing but no mutations of TSG101 in human breast cancer. Cancer Res. 57:1997;3131-3134.
9. Gayther S.A., Barski P., Batley S.J., Li L., de Foy K.A., Cohen S.N., Ponder B.A., Caldas C. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumors. Oncogene. 15:1997;2119-2126.
10. Willeke F., Ridder R., Bork P., Klaes R., Mechtersheimer G., Schwarzbach M., Zimmer D., Kloor M., Lehnert T., Herfarth C., von Knebel Doeberitz M. Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues. Mol Carcinogen. 23:1998;195-200.
11. Balló H., Koldovsky P., Hoffman M.T., Balz V., Hildebrandt B., Gerharz C.-D., Bier H. Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model. Anticancer Res. 19:1999;3827-3836.
12. Orita M., Iwahana H., Kanazawa H., Hayashi K., Sekiya T. Detection of polymorphism of human DNA by gel electrophoresis as single-strand conformation polymorphism. Proc Natl Acad Sci USA. 86:1989;2766-2770.
13. Hogervorst F.B.L., Cornelis R.S., Bout M., van Vliet M., Oosterwijk J.C., Olmer R., Bakker B., Klijn J.G.M., Vasen H.F.A., Meijers-Heijboer H., Menko F.H., Cornelisse C.J., den Dunnen J.T., Devilee P., van Ommen G.-J.P. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 10:1995;208-212.
14. Lu M.L., Conzen S.D., Cole C.N., Arrick B.A. Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells. Cancer Res. 56:1996;4578-4581.
15. Wilson C.A., Payton M.N., Elliott G.S., Buaas F.W., Cajulis E.E., Grosshans D., Ramos L., Reese D.M., Slamon D.J., Calzone F.J. Differential subcellular localization, expression and biological toxicity of BRCA1 and splice variant BRCA1-Δ11b. Oncogene. 14:1997;1-16.
16. Smith T.M., Lee M.K., Szabo C.I., Jerome N., McEuen M., Taylor M., Hood L., King M.-C. Complete genomic sequence and analysis of 117kb of human DNA containing the gene BRCA1. Genome Res. 6:1996;1029-1049.
17. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen-Strano A., Katcher H., Yakumo K., Gholami Z., Shaffer D., Stone S., Bayer S., Wray C., Bogden R., Dayanath P., Ward J., Tonin P., Narod S., Bristow P.K., Norris F.H., Helvering L., Morrison P., Rosteck P., Lai M., Barrett J.C., Lewis C., Neuhausen S., Cannon-Albright L., Goldgar D., Wiseman R., Kamb A., Skolnick M.H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
18. Durocher F., Shattuck-Eidens D., McClure M., Labrie F., Skolnick M.H., Goldgar D.E., Simard J. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet. 5:1996;835-842.
19. Rahman N., Stratton M.R. The genetics of breast cancer susceptibility. Ann Rev Genet. 32:1998;95-121.
20. Bienstock R.J., Darden T., Wiseman R., Pedersen L., Barrett J.C. Molecular modeling of the amino-terminal zinc ring domain of BRCA1. Cancer Res. 56:1996;2539-2545.
21. Scully R., Anderson S.F., Chao D.M., Wei W., Ye L., Young R.A., Livingston D.M., Parvin J.D. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA. 94:1997;5605-5610.
22. Rodenhiser D., Chakraborty P., Andrews J., Ainsworth P., Mancini D., Lopes E., Singh S. Heterogenous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs. Oncogene. 12:1996;2623-2629.
23. Krawczak M., Cooper D.N. Gene deletions causing human genetic disease. mechanisms of mutagenesis and the role of the local DNA sequence environment Hum Genet. 86:1991;425-441.
24. Serova O., Montagna M., Torchard D., Narod S.A., Tonin P., Sylla B., Lynch H.T., Feunteun J., Lenoir G.M. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet. 58:1996;42-51.
25. Breast Cancer Information Database (2001): Available at http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/bic/index.html.
26. Langston A.A., Stanford J.L., Wicklund K.G., Thompson J.D., Blazej R.G., Ostrander E.A. Germline BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet. 58:1996;881-885.
27. Offit K., Gilewski T., McGuire P., Schluger A., Hampel H., Brown K., Swensen J., Neuhausen S., Skolnick M., Norton L., Golgar D. Germline BRCA1 185DelAG mutations in Jewish women with breast cancer. Lancet. 347:1996;1643-1646.
28. FitzGerald M.G., MacDonald D.J., Krainer M., Hoover I., O'Neil E., Unsal H., Silva-Arrieto S., Finkelstein D.M., Beer-Romero P., Englert C., Sgroi D.C., Smith B.L., Younger J.W., Garber J.E., Duda R.B., Mayzel K.A., Isselbacher K.J., Friend S.H., Haber D.A. Germline BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 334:1996;143-149.
29. Friedman S.L., Ostermeyer E.A., Szabo C.I., Dowd P., Lynch E.D., Rowell S.E., King M.-C. Conformation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet. 8:1994;399-404.
30. Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drüsedau M., Hogervorst F.B.L., Hageman S., Arts P.J.W., Ligtenberg M.J.L., Meijers-Heijboer H., Klihn J.G.M., Vasen H.F.A., Cornelisse J.C., van't Veer L.J., Bakker E., van Ommen G.B.J., Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 17:1997;341-345.
31. Puget N., Torchard D., Serova-Sinilnikova O.M., Lynch H.T., Feunteun J., Lenoir G.M., Mazoyer S. A 1kb Alu-mediated germline deletion removing BRCA1 exon 17. Cancer Res. 57:1997;828-831.
32. Swensen J., Hoffman M., Skolnick M.H., Neuhausen S.L. Identification of a 14kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet. 6:1997;1513-1517.
33. Montagna M., Santacatterina M., Torri A., Menin C., Zullato D., Chieco-Bianchi L., D'Andrea E. Identification of a 3kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families. Oncogene. 18:1999;4160-4165.
34. Puget N., Sinilnikova O.M., Stoppa-Lyonet D., Audoynaud C., Pagès S., Lynch H.T., Goldgar D., Lenoir G.M., Mazoyer S. An Alu-mediated 6kb duplication in the BRCA1 gene. a new founder mutation? Am J Hum Genet. 64:1999;300-302.
35. Malkin D., Li F.P., Strong L.C., Fraumeni J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friens S.H. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238.
36. Borresen A.L. Role of genetic factors in breast cancer susceptibility. Acta Oncol. 31:1992;151-155.
37. Steiner P., Barnes D.M., Harris W.H., Weinberg R.A. Absence of rearrangements in the tumor susceptibility gene TSG101 in human breast cancer. Nat Genet. 16:1997;332-333.
38. Sun Z., Pan J., Bubley G., Balk S.P. Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene. 15:1997;3121-3125.
39. Lin S.-Y., Chen Y.-J., Chang J.-G. Multiple truncated transcripts of TSG101 in gastrointestinal cancers. J Gastroenterol Hepatol. 13:1998;1111-1114.
40. Sun Z., Pan J., Hope W.X., Cohen S.N., Balk S.P. Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer. 86:1999;689-696.
41. Lupas A. Coiled coils. new structures and new functions Trends Biochem Sci. 21:1996;375-382.
42. Xu C.F., Greenman J., Solomon E. Truncated TSG101 transcripts are present in peripheral blood from both familial breast cancer patients and controls. Eur J Cancer. 34:1998;1077-1080.